Logo

Silence Therapeutics Highlights its R&D Pipeline and Initiates Dose Escalation Studies for SLN360

Share this

Silence Therapeutics Highlights its R&D Pipeline and Initiates Dose Escalation Studies for SLN360

Shots:

  • The company highlights its lead candidate- SLN360 for CV disease associated with high Lp (a) levels and has received the US FDA’s IND approval to start dose-escalation studies in healthy volunteers and secondary prevention patients with elevated Lp(a). The company plans to start dosing healthy volunteers in the P-I study later this year
  • The company reveals that it has initiated a P-I study of SLN124 in 24 healthy volunteers for beta-thalassemia and MDS- marking the first dose of a Silence’s siRNA therapeutic delivered to humans using the GalNAc-siRNA platform. SLN124 has received the US FDA’s & EMA’s ODD for adult beta-thalassemia and FDA’s ODD for MDS and RPD for beta-thalassemia
  • Silence received $2M milestones for commencing its work on the second target being explored under its complement pathway RNAi collaboration with Mallinckrodt and is eligible to receive additional $2M milestones if work commences on a third target in the collaboration

­ Ref: Silence Therapeutics | Image: The Pharma Letter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions